<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5009806 Figure_1-B</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) Western blot analysis of lysates and media from wt and mutant N9 cells (N9 wt /mu) using antibody anti-murine TREM2 (clone 5F4), which is raised against the murine TREM2 extracellular domain. sTREM2, soluble TREM2 * Indicate unspecific bands. Anti-calnexin antibody was used as loading control.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_1-C</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Phagocytosis of 1 &#181;M HiLyte&#8482; Fluor 488 A&#946;1-42 (fA&#946;42) by N9 wt and N9 mu in the presence or absence of antibody 2D8 or the non-binding antibody 6687. Cytochalasin D (CytoD, 10 mM) was used as control to verify phagocytic uptake. (n = 4, +/- SEM; 2 way ANOVA, interaction P=0.61, genotype P&lt;0.0001, treatment P=0.0001; post hoc tests wt vs. mu for the following conditions: fA&#946;42 P=0.0043, fA&#946;42-2D8 P=0.0436).</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_1-D</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) Western blot of BMDM derived from wt and Trem2 knockout (ko) animals using antibody 5F4.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_1-E-F</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 1-E-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E-F</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Phagocytosis of fA&#946;42 by BMDM from wt and Trem2 ko animals in the presence or absence of 2D8, or the non-binding control antibody 6687. (n = 3, +/- SEM; 2 way ANOVA, interaction P=0.0005, genotype P&lt;0.0001, treatment P&lt;0.0001; post hoc tests wt vs. ko for the following conditions: fA&#946;42 P=0.0021, fA&#946;42-2D8 1 &#181;g/ml P&lt;0.0001, fA&#946;42-2D8 5 &#181;g/ml P&lt;0.0001, fA&#946;42-2D8 10 &#181;g/ml P&lt;0.0001, fA&#946;42/6687 10 &#181;g/ml P=0.0007) (F) Quantification of relative fA&#946;42uptake to lowest antibody concentration used.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_1-G-H</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 1-G-H</infon>
    <infon key="sourcedata_figure_dir">Figure_1-G-H</infon>
    <passage>
      <offset>0</offset>
      <text>(G) Phagocytosis of fA&#946;42 by BMDM from wt and Trem2 ko animals in the presence or absence of mAb11, or an isotype control antibody (IC). (n = 4, +/- SEM; 2 way ANOVA, interaction P=0.0223, genotype P&lt;0.0001, treatment P&lt;0.0001; post hoc tests wt vs. ko for the following conditions: fA&#946;42-mAb11 1 &#181;g/ml P=0.0391, fA&#946;42-mAb11 5 &#181;g/ml P=0.0069, fA&#946;42-mAb11 10 &#181;g/ml P&lt;0.0001, fA&#946;42-mAb11 20 &#181;g/ml P=0.0001, fA&#946;42-mAb11 50 &#181;g/ml P&lt;0.0001). (H) Quantification of relative fA&#946;42 uptake to lowest antibody concentration used.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_1-I</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 1-I</infon>
    <infon key="sourcedata_figure_dir">Figure_1-I</infon>
    <passage>
      <offset>0</offset>
      <text>(I) Recombinant mousesTREM2 does not rescue fA&#946;42 uptake in Trem2-deficient BMDM. Increasing amounts of sTREM2 were added to the media of wt or Trem2 ko BMDM in the presence or absence of mAb11 (10 &#181;g/ml).</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_1-J</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 1-J</infon>
    <infon key="sourcedata_figure_dir">Figure_1-J</infon>
    <passage>
      <offset>0</offset>
      <text>(J) Western blot of primary microglia from wt or Trem2 ko animals using antibody 5F4.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_1-K-L</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 1-K-L</infon>
    <infon key="sourcedata_figure_dir">Figure_1-K-L</infon>
    <passage>
      <offset>0</offset>
      <text>(K) Phagocytosis of fA&#946;42 by primary microglia from wt and Trem2 ko animals in the presence or absence of mAb11, or an isotype control antibody (IC). (n = 5, +/- SEM; 2 way ANOVA, interaction P=0.4797, genotype P&lt;0.0001, treatment P&lt;0.0001; post hoc tests wt vs. ko for the following conditions: fA&#946;42-mAb11 5 &#181;g/ml P=0.0449, fA&#946;42-mAb11 10 &#181;g/ml P=0.0370, fA&#946;42-mAb11 20 &#181;g/ml P=0.0299, fA&#946;42-mAb11 50 &#181;g/ml P=0.0120). (L) Quantification of relative fA&#946;42uptake to lowest antibody concentration used.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_2-A-B</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 2-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Representative histograms for Fc&#947;-receptors-PE (Fc&#947;R-PE) expression levels as used for quantification. Stacked histograms for log PE fluorescence intensity of wt and Trem2 ko BMDM are shown for the respective Fc&#947;R (I, IIB/III and IV). (B) Relative quantification of cell surface levels of Fc&#947;R molecules. Absolute number of cell surface Fc&#947;R-PE molecules was determined by the BD QuantiBRITE&#174; method (see methods section for details) and normalized to expression levels of the respective wt control. (n=4, +/- SEM, t test, two-tailed; wt vs. ko: Fc&#947;RI-PE P=0.0008, Fc&#947;RIIB/III-PE P=0.0033, Fc&#947;RIV-PE P=0.7001).</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_2-C</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 2-C</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) mRNA levels of Fc&#947;R are increased in Trem2 ko BMDM. Fold changes of the respective Fc&#947;R (I, IIB, III, IV) mRNA levels in Trem2 ko BMDM were determined by quantitative real-time PCR. (n=6, +/- SEM; one-sample t test, two-tailed; wt vs. ko: Fc&#947;RI P=0.0118, Fc&#947;RIIB P=0.0006, Fc&#947;RIII P=0.0004, Fc&#947;RIV P=0.0284)</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_2-D-E</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 2-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_2-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>(D) Phosphorylated Syk (P-Syk) and total Syk (T-Syk) levels were determined by western blotting in lysates from wt and Trem2 ko BMDM after 1 h treatment with A&#946; alone, together with antibody 2D8 (A&#946;-2D8), or an isotype control (A&#946;-IC). Actin was used as a loading control. (E) Quantification of P-Syk normalized to T-Syk. (n = 4, +/- SEM; 2 way ANOVA, interaction P=0.0490, genotype P=0.0898, treatment P&lt;0.0001. Bonferroni-corrected pair-wise post hoc tests, ** P =0.0075 vs. wt).</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_3-B</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) mAb11 but not the IC co-localized with methoxy-X04.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_3-C-D</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 3-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>BMDM (C) or primary microglia (D) were cultured on cryosections pre-incubated with mAb11 (1 &#181;g/ml). After 24 h, sections were processed for immunostaining using antibody against CD68 to identify myeloid cells and methoxy-X04 staining to visualize A&#946;. Note that both cell types internalize A&#946; into intracellular vesicles (right panels show enlargement of insets). Scale bar: 10&#181;m.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_4-A-B</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 4-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>(A) BMDM from wt or Trem2 ko mice were cultured on APP/PS1micebrain cryosections incubated with or without mAb11 (1 &#181;g/ml) or an isotype control (IC; 1 &#181;g/ml) for 24 h. Sections were then probed with methoxy-X04. Scale bar, 500 &#181;m.  (B) The amyloid plaque load was quantified from the entire sagittal section. Sections incubated with medium (no cell) were set as baseline. (n = 6, +/- SEM; 2 way ANOVA, interaction P&lt;0.0001, genotype P&lt;0.0001, treatment P&lt;0.0001; Tukey's multiple comparisons tests; wt vs. ko for the following conditions: no antibody P=0.0304, IC P=0.0049, mAb11 P=0.0212; wt : IC vs. wt : mAb11 P=0.0008; ko : IC vs. ko : mAb11 P=0.0001).</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_4-C-D</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 4-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>(C, D) Equal numbers of wt and Trem2 ko BMDM were added and cell numbers were analyzed after termination of experiments by quantifying the CD68 positive cells on top of the sections. (n = 4, +/-SEM; t-test; n.s., nonsignificant, P=0.5004). Scale bar, 200 &#181;m.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_4-E</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 4-E</infon>
    <infon key="sourcedata_figure_dir">Figure_4-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) A&#946; was extracted by urea buffer from replicate slices of the experiment shown in (A) and total A&#946; was identified by western blotting.</text>
    </passage>
  </document>
  <document>
    <id>5009806 Figure_5-A-B</id>
    <infon key="sourcedata_document">2082</infon>
    <infon key="doi">10.15252/emmm.201606370</infon>
    <infon key="pmc_id">5009806</infon>
    <infon key="figure">Figure 5-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Cryosections from unfixed brain of 6-months old APP/PS1mice were pre-incubated with increasing concentrations of mAb11 (0.001, 0.01, 0.1, 1, 5 &#181;g/ml). BMDM from wt or Trem2 ko mice were added for 24 h. Sections were stained with methoxy-X04. Scale bar, 500 &#181;m. (B) Methoxy-X04 signals were quantified from the entire sagittal section. (n = 5, +/- SEM; 2 way ANOVA, interaction P=0.0082, genotype P&lt;0.0001, treatment P&lt;0.0001. Fisher's LSD post hoc comparisons; * show statistics between wt and ko under the same experimental condition. # in black show wt compares to no antibody stimulation; # in grey show ko compares to no antibody stimulation; wt vs. ko for the following conditions: no antibody P=0.0053, mAb11 0.001 &#181;g/ml P=0.0003, mAb11 0.01 &#181;g/ml P&lt;0.0001, mAb11 0.1 &#181;g/ml P=0.0001, mAb11 1 &#181;g/ml P=0.0007, mAb11 5 &#181;g/ml P=0.0011; Following conditions compare to wt / no antibody: wt / mAb11 0.01 &#181;g/ml P=0.0166, wt / mAb11 0.1 &#181;g/ml P=0.0002, wt / mAb11 1 &#181;g/ml P&lt;0.0001, wt / mAb11 5 &#181;g/ml P&lt;0.0001; Following conditions compare to ko / no antibody: ko / mAb11 0.1 &#181;g/ml P=0.0099, ko / mAb11 1 &#181;g/ml P&lt;0.0001, ko / mAb11 5 &#181;g/ml P&lt;0.0001.</text>
    </passage>
  </document>
</collection>
